Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Feinberg School of Medicine at Northwestern University, discusses the importance of identifying and treating patients with follicular lymphoma (FL) who experience progression of their disease.
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Feinberg School of Medicine at Northwestern University, discusses the importance of identifying and treating patients with follicular lymphoma (FL) who experience progression of their disease.
Follicular lymphoma is a rapidly changing field, Winter explains. More recently, there is evidence showing the majority of FL patients will do well, however, 20% of patients will progress within the first 2 years. These patients will have a 5-year overall survival (OS) of 50%, compared to most patients who will have a median OS measured in decades.
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More